Anthropic CEO Dario Amodei met White House Chief of Staff Susie Wiles as the government reacts to its Mythos system that automates some of the work of cyberattacks.

That human-accountable model makes the most sense to me. By all means, integrate AI into the systems employees already use and let it take over the repetitive, time-consuming drudgery of the job. But we still need someone to vet the results and decide whether it makes sense.

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to support research in biology, drug discovery and translational medicine. | Following its recently announced partnership with Novo Nordisk,

Alibaba Group Holding Ltd. launched a new AI model that can be used to develop games and generate videos simulating the real world, expanding its suite of products to challenge Tencent Holdings Ltd. as it looks to monetize the technology.

Muse Spark, as what Meta Platforms (NASDAQ:META | META Price Prediction) is calling its much-anticipated closed-source model, which used to go by the codename Avocado. Undoubtedly, it’s an interesting name,

NVIDIA Corp. (NASDAQ:NVDA) is one of the 10 Best Data Center Stocks To Buy For the Long Term. In the past year, the stock grew 95.44%, while it posted 5.03% year-to-date growth.

OpenAI is rolling out an early version of an artificial intelligence model meant to speed up drug discoveries, joining a field of growing interest for tech companies eager to prove AI can pave the way for more scientific breakthroughs.

By Juby Babu April 16 - OpenAI on Thursday introduced an artificial intelligence model touting increased biology knowledge and scientific research capabilities, as the startup deepens its push into the life sciences field.

OpenAI's latest AI model is built to do far more than offer cooking advice or create a spreadsheet. GPT-Rosalind, the company's first model specifically built for life science, is meant to help scientists with drug discovery, biology and translational medicine.

Trump administration reconsiders Anthropic ban as CEO meets White House officials to discuss Mythos Preview, a powerful new AI cybersecurity model.